Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients).

About Motavizumab

Motavizumab, formerly known as Numax(R), is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. Phase 1 and Phase 2 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its first pivotal trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated a 26-percent reduction in RSV hospitalizations due to RSV and a 50-percent reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, its secondary endpoint.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RS
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 /PRNewswire/ ... CHDX ) today announced the completion of ... for $24.00 per share in cash.  Healthy Harmony is ... Ltd. ("Fosun") and Ms. Roberta Lipson , the ... merger agreement was adopted by Chindex,s stockholders at a ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Allakos ... additional $10 million investment from current investors to ... additional financing was completed following achievement of a ... antibody program, and represents an extension of the ... in December 2012. With this additional financing, Allakos ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 /PRNewswire/ ... Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ... de fusion définitif en vertu duquel Daiichi Sankyo ... en circulation d,Ambit Biosciences à 15 dollars par ... publique d,achat qui sera suivie d,une fusion avec ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... OMAHA, Neb., May 15 Creighton Medical Laboratories, based ... Omaha, announced today that it has become the first ... effective testing method for cancer. The method, called SNP ... laboratories to study cancer for several years. However, Creighton ...
... , in Damaged Tissue and Cells MANDEVILLE, La., ... leading expert in the field of non-surgical skin rejuvenation ... to speed up the healing process of damaged tissue ... a double-blinded, placebo-controlled clinical study of a glycerin-based bruise-reaction ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... Houstonians seeking the latest information about ... on the Internet. Paul Vitenas, JR. M.D., F.A.C.S., ... surgeons, has launched a new website to better inform ... Botox Cosmetic services. The new website can be ... the new website, Botox Cosmetic is a non-surgical injectable ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- For millions ... against excess weight and the threat of type 2 ... battle may be tougher for some than for others, ... promotes good health, it may not be as effective ... type 2 diabetes," said one expert, Dr. Ruth Loos, ...
(Date:9/30/2014)... 30, 2014 The global market for ... 38.75 billion by 2020 at an estimated CAGR of ... study by Grand View Research, Inc. Increasing prevalence of ... habits such as excessive alcohol consumption and growing geriatric ... is expected to serve this market as a high ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... the largest,provider of business services to orthodontic and ... Texas and Atlanta, Georgia to,better serve the company,s ... offices confirm our operating principle that the,heart of ... but in the,hundreds of practices we serve each ...
... INDIANAPOLIS Public health officials are constantly in ... a possible pandemic, but to fight these deadly ... need it faster. , Researchers from the Regenstrief ... have found that automated electronic medical laboratory reporting ...
... TALLAHASSEE, Fla. -- About 5,000 people around the world die ... been developed to combat it in 40 years. Researchers at ... hope to change that through research made possible by a ... award will make it possible for Timothy A. Cross, the ...
... their relatives wish to donate organs when they die, because ... protecting the body of the deceased, according to research in ... University of Southampton, UK, spoke to 26 people who had ... organ donations about their views and experiences. The 23 relatives ...
... China, Jan. 17 /Xinhua-PRNewswire-FirstCall/ -- China Nepstar,Chain ... Nepstar" or "the Company"), the,largest drugstore chain ... join the,Shenzhen Charity Federation to launch a ... health issues among low-income working women,residents in ...
... industry,s voluntary withdrawal of oral ... and cold medicines in October 2007, WASHINGTON, Jan. ... (OTC) cough and cold medicines, the Consumer Healthcare,Products Association ... Administration (FDA) decision against the use of oral OTC ...
Cached Medicine News:Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Battling potential disease outbreaks online 2Health News:Researcher, magnet lab receive $2 million grant to target tuberculosis 2Health News:Relatives who decline organ donations face conflict and guilt 2Health News:Relatives who decline organ donations face conflict and guilt 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 2Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 4Health News:CHPA Lends Support to FDA's Announcement Against Use of Oral, Over-the-Counter Cough and Cold Medicines in Children Under Two 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: